Drug companies are outsourcing manufacturing at record rates
Theme 1: CDMO Sector Hits Inflection Point on Patent Wins and Record Guidance Raises
The CDMO sector is experiencing a fundamental shift as pharmaceutical companies increasingly outsource manufacturing to eliminate capital investments and reduce operational risks. The U.S. CDMO market is projected to expand from $83.1 billion in 2025 to $149.4 billion by 2032, representing an 8.7% compound annual growth rate that has accelerated from the historical 7.7% CAGR.
Lonza's exceptional performance demonstrates the sector's momentum, with the world's largest CDMO raising its full-year outlook to 20-21% growth and EBITDA margins of 30-31%. Industry data shows eight of the top 10 CDMOs grew revenue in 2024, with combined revenue rising 5% to $31.8 billion.
Patent settlements like Esperion's create long-term visibility for manufacturing contracts, while international approvals expand addressable markets and guarantee additional milestone payments and royalties.
Stocks that would benefit:
ESPR: Esperion Therapeutics - Esperion's landmark patent settlement extending NEXLETOL's U.S. exclusivity to 2040 provides nearly two decades of guaranteed manufacturing demand for its CDMO partners. This settlement transforms the company's relationship with contract manufacturers from short-term to long-term strategic partnerships, as manufacturing capacity can now be planned with exceptional visibility. The recent Japanese approval for NEXLETOL further expands the global manufacturing footprint required, creating additional volume opportunities for CDMOs that can meet international regulatory standards. This patent protection directly supports the thesis of CDMOs securing decades-long revenue streams through intellectual property extensions. Read More →
TMO: Thermo Fisher Scientific - As a dominant force in the life sciences sector with significant CDMO operations, Thermo Fisher is uniquely positioned to capitalize on pharmaceutical companies' accelerating outsourcing trends. The company's diversified portfolio allows it to serve the entire drug development lifecycle, from early-stage research through commercial manufacturing. Thermo Fisher's sustained investment in high-impact innovation, particularly in bioproduction technologies, provides a significant competitive advantage in securing long-term manufacturing contracts. The company's global scale enables consistent market share gains as pharmaceutical companies increasingly prefer CDMOs with comprehensive capabilities and international reach, directly aligning with the thesis of CDMOs benefiting from the fundamental shift toward outsourced manufacturing. Read More →
CCRN: Cross Country Healthcare - While primarily known for healthcare staffing, Cross Country is strategically transforming into a diversified, tech-enabled workforce solutions provider that increasingly serves pharmaceutical manufacturers and CDMOs. The company's proprietary Intellify platform enhances operational efficiency for pharmaceutical clients, addressing the critical staffing challenges that CDMOs face during rapid expansion. As CDMOs scale operations to meet growing demand, Cross Country's specialized staffing solutions for pharmaceutical manufacturing environments become increasingly valuable. This positions the company to benefit from the same underlying trend of accelerated pharmaceutical outsourcing that is driving the CDMO sector's growth, particularly as labor constraints remain a key challenge for manufacturing expansion. Read More →
Theme 2: Renewable Energy Utilities Reach Market Share Tipping Point
Renewable energy has reached a critical inflection point, with wind and solar now providing more than 23% of total U.S. installed capacity and projected to overtake natural gas as the leading energy source by mid-2028. Solar is expected to add 92,631 MW of "high probability" capacity through July 2028, more than four times wind's 22,528 MW.
Major U.S. banks reduced fossil fuel project financing by 25% to $73 billion, indicating market-driven capital reallocation.
FERC projections show utility-scale solar reaching more than 17% of U.S. generating capacity by mid-2028, while policy support through the Inflation Reduction Act and technological advances in perovskite solar cells and energy storage create sustainable competitive moats.
Stocks that would benefit:
NEE: NextEra Energy - NextEra is uniquely positioned to capitalize on the renewable energy market share tipping point with its industry-leading $120 billion investment plan through 2029. The company's strategic foresight in supply chain diversification and "safe harboring" of projects through 2029 transforms potential industry headwinds into distinct competitive advantages, allowing it to deploy renewable capacity faster than competitors. NextEra's technological leadership, including AI-optimized grid operations and advanced battery storage solutions, provides a quantifiable edge in efficiency and cost, solidifying its competitive moat as renewables become the dominant power generation source. The company's diversified "all-of-the-above" energy portfolio and unmatched development capabilities enable it to meet the unprecedented surge in U.S. electricity demand driven by AI, manufacturing reshoring, and electrification. Read More →
NRG: NRG Energy - NRG is strategically positioned to benefit from the renewable energy tipping point through its transformative acquisition of LS Power's portfolio, which doubled its generation fleet and positioned it as naturally long against retail load in core markets. This expanded capacity significantly enhances NRG's ability to capitalize on the market transition toward renewables while maintaining reliability. The company's investments in Virtual Power Plant technology, including a 1 GW residential VPP target, offer a capital-efficient approach to renewable integration that enhances customer value while providing a competitive edge in distributed energy solutions. As renewables become the dominant generation source, NRG's integrated model allows it to capture value across the entire electricity value chain while managing the intermittency challenges inherent in high-renewable penetration markets. Read More →
CWEN: Clearway Energy - Clearway represents a pure-play opportunity to benefit from the renewable market share tipping point through its diversified portfolio of wind, solar, and energy storage assets. The company's focus on modern renewable technologies provides a competitive advantage, particularly its battery energy storage systems (BESS) fleet that consistently achieves high availability (98.5%-99%) and is strategically positioned for long-term tax credit eligibility. Clearway's disciplined capital allocation approach, funding growth primarily through retained Cash Available for Distribution and prudent use of its substantial excess debt capacity, ensures financial resilience as the company scales to meet growing renewable demand. The company's strategic repowering capabilities allow it to enhance existing assets through technology upgrades, creating additional value from its renewable portfolio as the sector achieves market dominance. Read More →
Theme 3: Vaccine Manufacturers Secure Revenue Visibility Through 2026 Respiratory Season
The transition from Emergency Use Authorization to full FDA approval for pediatric populations provides greater regulatory certainty and expanded market access for vaccine manufacturers. Moderna's strong clinical data showing 8-fold increases in neutralizing antibodies validates the variant-targeting approach and supports annual vaccine updates.
The FDA's approval of updated COVID-19 vaccines from multiple manufacturers targeting the LP.8.1 strain creates a competitive but expanding market opportunity as healthcare systems prepare for the 2025-2026 respiratory virus season. This establishes a predictable annual cycle similar to influenza vaccines.
Moderna's dual-product approach with traditional Spikevax and the refrigerator-stable mNexspike provides broader market coverage and differentiated storage advantages, while international approvals like Japan's authorization create additional revenue streams and milestone payments.
Stocks that would benefit:
MRNA: Moderna - Moderna is at the forefront of establishing predictable annual revenue cycles for COVID-19 vaccines with its dual-product strategy. The company's FDA approval for Spikevax in pediatric populations (six months through 11 years) transitions the product from emergency authorization to standard approval, providing greater regulatory certainty and expanded market access ahead of the 2025-2026 respiratory season. Moderna's impressive clinical data showing greater than 8-fold increases in neutralizing antibodies against the LP.8.1 variant validates its variant-targeting approach and supports the annual update model. The company's differentiated strategy of offering both traditional Spikevax and the next-generation refrigerator-stable mNexspike provides broader market coverage and storage advantages that directly support the thesis of creating a sustainable annual vaccination business model similar to influenza. Read More →
BNTX: BioNTech - BioNTech is strategically leveraging its COVID-19 vaccine franchise to establish predictable annual revenue cycles while simultaneously transforming into a multi-product oncology powerhouse. The company's strong cash position of €16 billion (as of Q2 2025) from its COVID-19 vaccine success provides exceptional financial flexibility to fund both its continued respiratory vaccine programs and ambitious oncology pipeline. BioNTech's mRNA platform technology allows it to rapidly update vaccine formulations to target emerging variants, supporting the annual update model that is central to creating sustainable revenue visibility. The company's global manufacturing and distribution capabilities, established during the pandemic, provide a competitive advantage in reliably supplying updated vaccines for each respiratory season, directly supporting the thesis of transitioning from emergency response to predictable annual vaccination cycles. Read More →
Join our Discord community to give feedback, request features, or ask questions about the newsletter or website.
https://discord.gg/yePwyWrwJBThe content is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk. Past performance is not indicative of future results. Investments may lose value and are not guaranteed.
Stay Updated
Get the latest Investment Themes of the Week delivered to your inbox every Monday.
View All Investment Themes
